The stimulation of bone mass by intermittent PTH treatment demonstrated the efficacy of the intervention in trisomy 21 and supports the idea that PTH or other potential anabolic treatments, such as anti-sclerostin antibody [41], [42], may have utility in DS patients with low BMD and low bone turnover. The gene discussed is PTH; the disease is Dravet syndrome.